Download

Bayer AG

Drug donations to clinical trials, facilitated the approval of Nifurtimox-Eflornithine combination therapy for Sleeping Sickness in April 2009.
Bayer has made a renewed five-year commitment to the WHO regarding its single-drug donation program for sleeping sickness and Chagas disease.

Bayer has made a renewed five-year commitment to the WHO regarding its single-drug donation program for sleeping sickness and Chagas disease.
The company signed a collaborative agreement with USAID in September 2009 to ensure equitable pricing in 11 Index Countries for microgynon. For ranking, contraceptives are outside the disease scope of Index 2010.
In 2008, Bayer implemented a new ATM strategy "Social Healthcare Programs" to place a greater emphasis on sustainability, on developing world needs and on Bayer's areas of expertise.
The company rolled out a new corporate compliance policy and systems plus a code for responsible lobbying during the period of analysis.
There is evidence of new agreements with WHO to contribute to the strengthening of pharmacovigilance structures and capacity in India and China.
Bayer continues its collaboration with the TB Alliance for clinical trial (in Phase III) of Moxifloxacin for MDR-TB – there are provisions in the agreement for affordable delivery of the product in the developing world.
During the period of analysis the company attempted to block the registration (obtaining marketing approval) of products by generics companies in an Indian court based on patent-registration linkage arguments. The company's claim was rejected by the court.

Bayer has limited R&D activity for the neglected diseases compared to the leading companies under coverage.
Bayer does not engage in non-exclusive voluntary licensing programs with generics companies.
The company does not have short- and long-term, qualitative and quantitative targets, which would reflect the breadth of its current ATM practices and facilitate progress reporting.
The company has limited public disclosure of program resources and output, advocacy activities, stance on patent-related issues (including TRIPS flexibilities) and post-trial access, which are all issues with potential ATM impact.